ArticleJournal of neuro-oncology2009
Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors.
Article in Journal of neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Current research trends and hotspots of boron neutron capture therapy: a bibliometric and visualization analysis.Frontiers in oncology · 2024Pooled it
- Nanotechnology in neurosurgery: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Pooled it
- Dendritic Structures Functionalized with Boron Clusters, in Particular Carboranes, and Their Biological Properties.Pharmaceutics · 2023Review
- Boron Neutron Capture Therapy: Clinical Application and Research Progress.Current oncology (Toronto, Ont.) · 2022Review
- Theranostics in Boron Neutron Capture Therapy.Life (Basel, Switzerland) · 2021Review
- Recent Developments in Nanomedicine for Pediatric Cancer.Journal of clinical medicine · 2021Review
- Boron neutron capture therapy: Current status and future perspectives.Cancer communications (London, England) · 2020Review
- Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.Frontiers in chemistry · 2020Review
- Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency.Cancers · 2019Review
- Boron delivery agents for neutron capture therapy of cancer.Cancer communications (London, England) · 2018Review
- Boron Neutron Capture Therapy for Malignant Brain Tumors.Neurologia medico-chirurgica · 2016Review
- Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform.Nano letters · 2016Article
- Recent advances in targeted drug delivery approaches using dendritic polymers.Biomaterials science · 2015Article
- Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.Advanced drug delivery reviews · 2014Review
- Nanocarrier-based therapies for CNS tumors.CNS oncology · 2014Review
- Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer.Radiation oncology (London, England) · 2012Review
- Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals.Chemical Society reviews · 2011Review
- Article
- Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis.Pharmaceutical research · 2010Review
- Advances in image-guided intratumoral drug delivery techniques.Therapeutic delivery · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
In the present study, we have evaluated a boronated dendrimer-epidermal growth factor (BD-EGF) bioconjugate as a molecular targeting agent for boron neutron capture therapy (BNCT) of the human EGFR gene-transfected F98 rat glioma, designated F98(EGFR). EGF was chemically linked to a heavily boronated polyamidoamine dendrimer (BD) by means of the heterobifunctional reagent, mMBS. Biodistribution studies were carried out at 6 h and 24 h following intratumoral (i.t.) injection or intracerebral (i.c.) convection enhanced delivery (CED) of (125)I-labeled or unlabeled BD-EGF (40 microg (10)B/10 microg EGF) to F98 glioma bearing rats. At 24 h. there was 43% more radioactivity in EGFR(+) tumors following CED compared to i.t. injection, and a doubling of the tumor boron concentration (22.3 microg/g vs. 11.7 microg/g). CED of BD-EGF resulted in a 7.2x increase in the volume of distribution within the infused cerebral hemisphere and a 1.9x increase in tumor uptake of BD-EGF compared with i.t. injection. Based on these favorable biodistribution data, BNCT was carried out at the Massachusetts Institute of Technology nuclear reactor 14 days following i.c. tumor implantation and 24 h. after CED of BD-EGF. These animals had a MST of 54.1 +/- 4.7 days compared to 43.0 +/- 2.8 days following i.t. injection. Rats that received BD-EGF by CED in combination with i.v. boronophenylalanine (BPA), which has been used in both experimental and clinical studies, had a MST of 86.0 +/- 28.1 days compared to 39.8 +/- 1.6 days for i.v. BPA alone (P < 0.01), 30.9 +/- 1.4 days for irradiated controls and 25.1 +/- 1.0 days for untreated controls (overall P < 0.0001). These data have demonstrated that the efficacy of BNCT was significantly increased (P < 0.006), following i.c CED of BD-EGF compared to i.t injection, and that the survival data were equivalent to those previously reported by us using the boronated anti-human-EGF mAb, C225 (cetuximab).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.